Stephen Castaneda - Concepedia

Concepedia

Author

Stephen Castaneda

Bristol-Myers Squibb (United States)

Also Known As

S. Castaneda, Stephen Castaneda, Stephen P. Castaneda

30

Publications

2.2K

Citations

11

H-Index

26

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)Eli Lilly (United States)

SC

About

Stephen Castaneda is an author at Bristol-Myers Squibb (United States) specializing in cancer research, pharmacology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	1.5K
2	Cell Biology	3	3	101
3	Biomolecular Engineering	1	1	28
4	Immunology	1	1	32
5	Pathology	1	1	62

Stephen Castaneda

×

12

Publications

2.2K

Citations

11

H-Index

	Year	Citations
Discovery of <i>N</i>-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays Louis J. Lombardo, Francis Y. Lee, Ping Chen, Journal of Medicinal Chemistry Drug TargetPreclinical AssaysPharmacotherapyCompound 13Pharmaceutical Chemistry	2004	1.3K
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade Rikke Holmgaard, David Schaer, Yanxia Li, Journal for ImmunoTherapy of Cancer	2018	358
Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure Feng Luo, Zheng Yang, Amy Camuso, Clinical Cancer Research	2006	149
Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft Feng Luo, Zheng Yang, Huijing Dong, Cancer Chemotherapy and Pharmacology OncologyAntitumor ActivityNude MiceMedicineAnti-cancer Agent	2005	85
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels Robert A. Wild, Krista Fager, Christine Flefleh, Molecular Cancer Therapeutics Tumor BiologyWidr ModelsMedicineGrowth Factor ReceptorPharmacology	2006	62
Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer Yixian Zhang, Stephen Castaneda, Melissa Dumble, Molecular Cancer Therapeutics	2011	46
Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple <i>In vivo</i> Tumor Models Francis Y. F. Lee, Kelly L. Covello, Stephen Castaneda, Clinical Cancer Research	2008	44
BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo Francis Y. Lee, Louis J. Lombardo, Amy Camuso, Cancer Research Chemoprevention StrategyCancer TypesCancer BiologyTumor BiologyMolecular Pharmacology	2005	41
Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers F. Y. Lee, Stephen Castaneda, Ivan Inigo, Journal of Clinical Oncology Breast OncologyImmunologyImmunotherapeuticsCancer BiologyGene Expression Profiling	2005	32
Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor Huaxing Pei, Saravanan Parthasarathy, Sajan Joseph, Cancer Research Drug TargetImmunotherapeuticsCancer BiologyTumor BiologyMolecular Pharmacology	2017	28

Page 1